AstraZeneca Buys Into COVID-19 Antibodies From Newly Launched RQ Bio
Spin-Out From UK’s Antibody Taskforce
Executive Summary
The big pharma company and its new partner both expect demand to continue for pre-exposure prophylaxis antibody therapies, for COVID-19 and beyond.
You may also be interested in...
Deal Watch: Innoviva To Buy The Rest Of Entasis For Enterprise Value Of $113m
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.
Coronavirus Notebook: WHO Says Extra Vaccine Boosters Confer Some Limited Benefits, Emergex & Zosano Link Up On T Cell Vaccine Patch
International regulators have issued an updated statement on the benefits and safety of COVID-19 vaccines for use by health professionals, while the UK BioIndustry Association has welcomed a MAb licensing deal between AstraZeneca and UK-based biotech firm RQ Bio.
Sanofi And AstraZeneca Still Lead In RSV But Pfizer Has Chance To Challenge
Sanofi and AstraZeneca’s antibody nirsevimab is still likely to reach the market first, but Pfizer could be close behind with superior efficacy results.